# Oral TGF-beta Receptor I Inhibitor Vactosertib in SOC Chemoradiotherapy for Esophageal Adenocarcinoma

> **NCT06044311** · PHASE2 · SUSPENDED · sponsor: **Melissa Lumish** · enrollment: 30 (estimated)

## Conditions studied

- Adenocarcinoma Esophagus
- Locally Advanced Adenocarcinoma
- Siewert Type I Adenocarcinoma of Esophagogastric Junction
- Siewert Type II Adenocarcinoma of Esophagogastric Junction

## Interventions

- **DRUG:** Vactosertib
- **DRUG:** Standard of Care Preoperative Therapy

## Key facts

- **NCT ID:** NCT06044311
- **Lead sponsor:** Melissa Lumish
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2024-09-30
- **Primary completion:** 2026-12-31
- **Final completion:** 2027-06-01
- **Target enrollment:** 30 (ESTIMATED)
- **Why stopped:** Major revisions due
- **Last updated:** 2026-05-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06044311

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06044311, "Oral TGF-beta Receptor I Inhibitor Vactosertib in SOC Chemoradiotherapy for Esophageal Adenocarcinoma". Retrieved via AI Analytics 2026-08-03 from https://api.ai-analytics.org/clinical/NCT06044311. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*